Qube Research & Technologies (QRT)
ADCT icon

Qube Research & Technologies (QRT)’s ADC Therapeutics ADCT Stock Holding History

Qube Research & Technologies (QRT)’s Portfolio ADCT Stock Details ADCT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q1 		– Sell
-207
Closed -$344 – 4411
2023
Q4 		$344 Hold
207
– – ﹤0.01% 3945
2023
Q3 		$186 Sell
207
-69,669
-100% -$92.7K ﹤0.01% 3734
2023
Q2 		$150K Sell
69,876
-7,290
-9% -$16.4K ﹤0.01% 1863
2023
Q1 		$150K Buy
+77,166
New +$285K ﹤0.01% 2022

Other funds holding ADCT

RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
PM
Prosight Management Dallas, Texas $610M AUM 40.86% 1-Year Est. Return
Morgan Stanley
Morgan Stanley New York $1.66T AUM 25.57% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.37T AUM 24.88% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
Citadel Advisors
Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return
VCG
Vantage Consulting Group Virginia Beach, Virginia $19.7M AUM 280.87% 1-Year Est. Return
BOCH
Blue Owl Capital Holdings New York $372M AUM 78.25% 1-Year Est. Return

Qube Research & Technologies (QRT)'s ADCT Position: Q1 2024 in Review

Qube Research & Technologies (QRT) sold out of ADC Therapeutics (ADCT) in Q1 2024, closing a stake of 207 shares — an estimated $344 sold.

Qube Research & Technologies (QRT) first reported a position in ADCT in Q1 2023 and held it in 4 quarters. The position peaked at $150K in Q1 2023. 36 funds tracked by Wall St. Rank hold ADCT as of Q1 2024.

  • Qube Research & Technologies (QRT) reported no remaining ADC Therapeutics position as of Q1 2024 after selling out during the quarter.
  • Qube Research & Technologies (QRT) sold 207 ADC Therapeutics shares in Q1 2024, an estimated $344.
  • Qube Research & Technologies (QRT) first reported a position in ADC Therapeutics in Q1 2023 and held it in 4 quarters.
  • Qube Research & Technologies (QRT)'s ADC Therapeutics position peaked at $150K in Q1 2023.
  • 36 funds tracked by Wall St. Rank held ADC Therapeutics as of Q1 2024.

Based on Qube Research & Technologies (QRT)'s 13F filing for Q1 2024, filed 14 May 2024.